Jovan Borjan

Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period

Hiba Dagher, Anne‐Marie Chaftari, Ishwaria M. Subbiah et al. · eLife · 2023 · 42 citations · Full text

Medicine, Infectious Diseases, Oncology +16

High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients

Uri Greenbaum, Kimberly Klein, Fernando D. Martínez et al. · Frontiers in Immunology · 2021 · 28 citations · Full text

Medicine, Infectious Diseases, Oncology +13

Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis

Jovan Borjan, Kevin A. Meyer, Ryan K. Shields et al. · International Journal of Antimicrobial Agents · 2019 · 26 citations

Life Sciences, Infectious Diseases, Microbiology +13

High-level ceftazidime/avibactam resistance in <i>Escherichia coli</i> conferred by the novel plasmid-mediated β-lactamase CMY-185 variant

William C. Shropshire, Bradley T. Endres, Jovan Borjan et al. · Journal of Antimicrobial Chemotherapy · 2023 · 21 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship

Issam Raad, Ray Hachem, Masayuki Nigo et al. · eLife · 2023 · 18 citations · Full text

Medicine, Oncology, Cancer Epidemiology +15